Investigational New Drug
- India
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
LA CHAUX DU FONDS, Switzerland: Rhizen announces the approval of its IND by USFDA for its oral DHODH inhibitor for…
Read More » - World
LG Chem Life Sciences and TransThera Biosciences Announce FDA Clearance of IND for TT-01025, a SSAO/VAP-1 Inhibitor
Nanjing, China & Seoul, Korea: LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co.…
Read More »